Status:

COMPLETED

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

Lead Sponsor:

Teijin America, Inc.

Conditions:

Diabetic Kidney Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary albumin-to-creatinine r...

Eligibility Criteria

Inclusion

  • Type 2 diabetes treated with ≥1 glucose-lowering medication for at least 12 months
  • UACR 200 to 3000 mg/g
  • eGFR ≥30 ml/min/1.73m2
  • Treated with at least the minimal recommended dose of an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB), but not both

Exclusion

  • History of Type 1 diabetes
  • Women who are breast feeding
  • Treatment with any uric acid-lowering therapy within previous 2 weeks
  • History of intolerance to any XO (xanthine oxidase) inhibitor
  • History of a gout flare requiring pharmacologic treatment
  • History or presence of tophaceous gout
  • History of immunosuppressant treatment for any known or suspected renal disorder
  • History of a non-diabetic form of renal disease
  • Glycosylated hemoglobin (HbA1c) \>11%
  • sUA \<4.0 mg/dL or \>10.0 mg/dL
  • Positive urinary pregnancy test
  • Dialysis for acute renal failure within previous 6 months
  • Renal allograft in place or a scheduled kidney transplant within the next 22 weeks
  • Congenital or acquired solitary kidney

Key Trial Info

Start Date :

April 10 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 4 2019

Estimated Enrollment :

130 Patients enrolled

Trial Details

Trial ID

NCT03449199

Start Date

April 10 2018

End Date

June 4 2019

Last Update

August 30 2022

Active Locations (55)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (55 locations)

1

AKDHC Medical Research Services, LLC

Flagstaff, Arizona, United States, 86001

2

Aventiv Research Inc.

Mesa, Arizona, United States, 85210

3

Comprehensive Research Institute

Alhambra, California, United States, 91801

4

California Kidney Specialists

Covina, California, United States, 91723

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria | DecenTrialz